Enable AI-poweredDetect new paradigm
Redefining on-site detection with chips and algorithms
About Us
Hangzhou BioChip.AI Co., Ltd. was established in March 2025. Leveraging globally leading ultra-high-density novel biochip technology (hereinafter referred to as the “novel biochip”), the company can rapidly, conveniently, simply, cost-effectively, and portably detect a wide variety of targets—including nucleic acids, proteins, and metabolites—to generate massive volumes of data. This enables the detection and characterization of complex, dynamic systems such as immune systems and microecosystems, making possible a new AI-powered detection paradigm.
At the same time, the company’s companion portable instruments allow on-site sample testing anytime and anywhere, greatly improving turnaround time while eliminating the risks and costs associated with sample transportation. Its core technologies and solutions hold diverse future application scenarios across multiple industries. They can drive innovation and transformation in areas such as respiratory pathogen detection and the relationship between gut and oral microbiota and wellness, while also delivering continuous value in smart agriculture (e.g., dairy and livestock industries), soil microorganism and soil ecology monitoring and regulation, synthetic biology (e.g., liquid fermentation microbial community refining and optimization), and AI multimodal big-data algorithms and platform development. As such, the company enjoys broad market prospects and significant potential social value.
The company’s core technical team brings together multidisciplinary talent spanning molecular diagnostics, bioinformatics, artificial intelligence, semiconductor nanofabrication, and microfluidic precision instrumentation. Team members are graduates of Tsinghua University, Peking University, and the Harbin Institute of Technology, and are joined by a professor from Westlake University. Through cross-disciplinary collaborative innovation, the team integrates cutting-edge technologies and innovative strengths from each field, establishing core technologies and fabrication processes for ultra-high-density novel biochips that are unprecedented worldwide.

Professional Team
Interdisciplinary collaborative innovation, integrating cutting-edge technologies
Xu Junpu
ChairmanMBA
- B.S., Biology, Tsinghua University
- MBA, CTU, USA
- Founder of Beijing ACCB Biotech
- 20 years of IVD industry experience
- Outstanding Overseas-Returned Entrepreneur of Zhongguancun
- Top 10 Leading Talent in Jiaxing
Prof. Li Xijun
Chief Scientist
- Director, Chip Digital Manufacturing Technology Research Center, Westlake University
- Proposer of the world’s first programmable photolithography mask
- Zhejiang Province Distinguished Expert
- Early pioneer of LNoI
- 40+ international patents; focused on micro/nano fabrication and maskless lithography
Mr. Chen
Technical Director
- Ph.D., School of Life Sciences, Tsinghua University
- Joint training at UCSF
- Beijing Nova Program recipient
- Beijing Science and Technology Award recipient
Mr. Hou
Bioinformatics Director
- M.S. in Bioinformatics, Harbin Institute of Technology
- Former mNGS project lead at EUROIMMUN China Medical Diagnostics
- Formerly responsible for bioinformatics analysis at Gene-X Health and Annoroad
Our Journey
Innovate continuously, move forward steadily.
Oral microecology detection automation device approved and generating sales revenue
Launched automated POCT device for oral microecology detection
Completed first mass-production tape-out of oral microbiota detection biochips
Closed Pre-A round financing
Applied for Chinese invention patents (DMD + vapor-phase synthesis)
Filed US core patent PCT application
